Page 24 – PHI

Man walking behind glass door next to a Sahlgren Academy poster

Sahlgrenska Acquires Second HoloMonitor System

After an initial purchase by Sahlgrenska University Hospital, Sahlgrenska Center for Cancer Research acquires a second HoloMonitor system.

The HoloMonitor M4 cell culture microscope on a lab bench next to cell culture accessories

HoloMonitor How-to Tutorials

Learn how to handle the HoloMonitor Live Cell Imaging & Analysis System.

Succeed in tracking your cells

We at PHI are always happy to hear from you, our customers, and receive feedback and suggestions on improving your HoloMonitor® experience. Therefore, we are excited to say that we have focused on realizing many of your suggestions with the latest software update, resulting in a new and advanced Single Cell Tracking analysis.

The HoloMonitor live cell imaging system inside a BioSpherix Xvivo incubator investor relations

BioSpherix Partnership Yields HoloMonitor Customer in Regenerative Medicine

Recently, the EU-funded Centre for Innovative Medicine in Vilnius purchased its first HoloMonitor analyzer for use in the center’s incubator system from BioSpherix.

Massachusetts Eye and Ear Infirmary building

Harvard Researchers Purchase HoloMonitor

Partners HealthCare International in Boston, Massachusetts, recently ordered its first and fully equipped HoloMonitor unit.

Interim Report 3 (2020-11-01 – 2021-01-31)

The second wave of the pandemic restricted sales during the 3rd quarter. However, the situation has improved significantly since late January.

Sequence of images showing cell divisions, created by the incubator-based cell culture microscope - HoloMonitor

Can We Trust Our Cell-based Experiments?

Our 3-part webinar series explored in the fields of cancer research, stem cell research and for in vitro drug development, how relevant conditions lead to relevant answers in cell culture.

PHI Secure Working Capital Until 2023

PHI has received a second loan commitment of 20 MSEK. In total, the company has received loan commitments of 35 MSEK that are expected to secure the company’s working capital until 2023.